The ability to reduce both tau and αSyn pathologies with a single small molecule HDAC6 inhibitor has therapeutic appeal, not only because such a molecule might be used to treat both tauopathies and α-synucleinopathies, but also because these pathologies often coexist in patients. This evidence concerns the gene MAPT and synucleinopathy.